Lorazepam Pediatric Dose — Sedation & Anxiolysis
Lorazepam is a intermediate-acting benzodiazepine that exerts its effects by potentiating GABA-mediated inhibition in the central nervous system. It is commonly used in pediatric practice for sedation, anxiolysis, and as an adjunct in the management of agitation or procedural anxiety. Its predictable pharmacokinetics and availability in both intravenous and oral formulations make it a practical choice across a variety of clinical settings.
Pediatric Dosing
The standard pediatric dose of lorazepam for sedation or anxiolysis is 0.05–0.1 mg/kg per dose, administered IV or PO, every 6 hours. The maximum single dose is 4 mg, regardless of weight.
- Route: IV or PO
- Dose: 0.05–0.1 mg/kg per dose
- Frequency: Every 6 hours
- Maximum single dose: 4 mg
Worked example: For a 20 kg child: 20 × 0.05 mg/kg = 1 mg (low end) to 20 × 0.1 mg/kg = 2 mg (high end) per dose. For a 50 kg adolescent, the weight-based calculation (2.5–5 mg) would be capped at the maximum of 4 mg per dose.
Indications and Clinical Context
Lorazepam is indicated for sedation and anxiolysis in pediatric patients across inpatient, procedural, and critical care settings. It is also used for the management of acute agitation and as part of multimodal sedation regimens in the PICU. As a benzodiazepine, lorazepam may be selected when anxiolysis with mild sedation is desired without significant analgesic requirements.
In procedural settings, lorazepam provides reliable anxiolysis and anterograde amnesia. Clinicians should select the lowest effective dose within the 0.05–0.1 mg/kg range based on the patient’s clinical status, weight, and concomitant medications. Consult institutional protocol for use in neonates or patients with hepatic impairment, as pharmacokinetics may be significantly altered in these populations.
Administration and Monitoring
Lorazepam may be administered intravenously as a slow bolus or given orally depending on the clinical scenario and patient access. IV administration allows for more predictable onset (typically 2–5 minutes) compared to the oral route (onset 20–30 minutes). Monitor patients for respiratory depression, excessive sedation, and hypotension, particularly when combined with opioids or other CNS depressants.
- Ensure resuscitative equipment is available when administering IV doses.
- Use with caution in patients with respiratory compromise or airway instability.
- Avoid abrupt discontinuation after prolonged use; taper per institutional protocol to prevent withdrawal.
- The maximum single dose of 4 mg should not be exceeded regardless of weight.
- Propylene glycol accumulation is a concern with high-dose or prolonged IV infusions; consult institutional protocol for extended use.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.